To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.
Name: Irinotecan
Description: Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29) Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.Type: DrugIrinotecan, Bevacizumab and FDOPA-PET/MRI imaging
Name: Bevacizumab
Description: Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.Type: DrugIrinotecan, Bevacizumab and FDOPA-PET/MRI imaging
Name: FDOPA-PET/MRI imaging
Description: FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapseType: DeviceIrinotecan, Bevacizumab and FDOPA-PET/MRI imaging
Description: The imaging is evaluated: (a) the uptake of PET tracer FDOPA measured by average and maximal standardized uptake values (SUVs) as well as tumor to normal brain ratios; and (b) tumor volumes defined by MRI signal abnormality.
Measure: FDOPA-PET/MRI imaging Time: 1 yearSingle Group Assignment
There is one SNP
- Patient must not have a known thrombophilic condition (i.e. protein S, protein C or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia, or antiphospholipid antibody syndrome). --- G20210A ---